GlassScriptPhysician profile
Diana Superfin
NPI 1750365953
$48,667.56
in general payments reported to CMS, 2019-2025
95 companies · $9,827 in 2025
The $9,827 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,825 · 2020: $3,613 · 2021: $3,570 · 2022: $7,062 · 2023: $7,300 · 2024: $10K · 2025: $9,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $8,953 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,490 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,054.52 |
| Consulting Fee | $8,952.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,490.01 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,646.43 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| Glaxosmithkline, LLC. | $5,279.13 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Kite Pharma, INC. | $3,735.73 | 2020-2024 | Yescarta |
| Avyxa Pharma, LLC | $3,678.12 | 2025 | |
| Janssen Biotech, INC. | $2,986.49 | 2019-2025 | Erleada, Darzalex, Rybrevant |
| Pfizer INC. | $2,009.59 | 2019-2025 | |
| Puma Biotechnology, INC. | $1,640.96 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,518.56 | 2019-2025 | Opdivo |
| Astellas Pharma US INC | $1,461.06 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Celgene Corporation | $1,442.15 | 2019-2025 | Reblozyl, Opdualag, Breyanzi |
| Novartis Pharmaceuticals Corporation | $1,165.39 | 2019-2025 | |
| Amgen INC. | $895.08 | 2019-2024 | Nplate, Xgeva, Vectibix |
| Seagen INC. | $880.43 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Genentech USA, INC. | $872.36 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Merck Sharp & Dohme LLC | $859.51 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
Show all 95 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $853.30 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Genzyme Corporation | $787.86 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $686.31 | 2019-2025 | Ninlaro, Iclusig, Alunbrig |
| Lilly USA, LLC | $653.20 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $626.99 | 2019-2023 | Imbruvica, Epkinly |
| Eisai INC. | $612.06 | 2019-2025 | |
| Tersera Therapeutics LLC | $554.19 | 2019-2025 | Zoladex, Quzyttir, Xermelo |
| Octapharma USA, INC. | $411.20 | 2019-2025 | Octagam Immune Globulin (Human) |
| Bayer Healthcare Pharmaceuticals INC. | $397.81 | 2019-2025 | |
| Incyte Corporation | $383.63 | 2019-2025 | Jakafi, Monjuvi, Niktimvo |
| Array Biopharma INC | $357.41 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Abbvie INC. | $354.21 | 2019-2025 | Venclexta |
| Stemline Therapeutics INC. | $350.12 | 2019-2025 | Orserdu |
| Exelixis INC. | $319.11 | 2019-2025 | Cabometyx |
| Myovant Sciences INC. | $314.36 | 2021-2022 | |
| Gilead Sciences, INC. | $271.50 | 2019-2025 | Trodelvy |
| Foundation Medicine, INC. | $267.80 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $258.59 | 2019-2025 | Zepzelca |
| Beigene USA, INC. | $251.38 | 2020-2025 | Brukinsa |
| Emd Serono, INC. | $247.88 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $223.45 | 2019-2025 | Ultomiris |
| Springworks Therapeutics, INC. | $216.18 | 2024-2025 | Ogsiveo, Gomekli |
| Regeneron Healthcare Solutions, INC. | $198.84 | 2021-2025 | Libtayo, Lynozyfic |
| Spectrum Pharmaceuticals INC. | $195.91 | 2023-2025 | Rolvedon |
| Karyopharm Therapeutics INC. | $183.05 | 2020-2023 | Xpovio |
| Sobi, INC | $178.64 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $170.79 | 2023 | Orgovyx |
| Epizyme, INC. | $165.97 | 2020-2022 | |
| Clovis Oncology, INC. | $165.70 | 2019-2022 | |
| Deciphera Pharmaceuticals INC. | $147.13 | 2022-2025 | Qinlock, Romvimza, Tgct |
| Aveo Pharmaceuticals, INC. | $136.63 | 2022-2025 | Fotivda |
| Kyowa Kirin, INC. | $132.60 | 2019-2025 | Poteligeo |
| Blueprint Medicines Corporation | $125.96 | 2020-2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.91 | 2019-2024 | Gilotrif |
| Servier Pharmaceuticals LLC | $118.12 | 2021-2024 | |
| Fresenius Kabi USA, LLC | $106.07 | 2023-2025 | Stimufend |
| Dendreon Pharmaceuticals LLC | $99.04 | 2021-2023 | Provenge |
| Tesaro, INC. | $97.74 | 2019 | |
| Recordati_rare_diseases_inc. | $92.36 | 2024-2025 | Sylvant, Enjaymo |
| Ipsen Biopharmaceuticals, INC | $89.84 | 2019-2024 | Onivyde |
| Coherus Oncology, INC. | $87.24 | 2024-2025 | Udenyca, Loqtorzi |
| Heron Therapeutics, INC. | $84.09 | 2020-2022 | |
| Taiho Oncology, INC. | $83.32 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $79.20 | 2019-2020 | |
| Beone Medicines USA, INC. | $77.88 | 2025 | Tevimbra, Brukinsa |
| Sun Pharmaceutical Industries INC. | $77.59 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $76.24 | 2019-2022 | |
| Pharmaessentia USA Corporation | $62.36 | 2022-2025 | Besremi |
| Immunocore Limited | $62.03 | 2024 | Kimmtrak |
| Aurobindo Pharma USA, INC. | $61.01 | 2020 | |
| Syndax Pharmaceuticals, INC. | $54.92 | 2025 | |
| Genmab U.S., INC. | $53.25 | 2023-2024 | Epkinly |
| Acrotech Biopharma INC. | $53.14 | 2021 | |
| Pharmacosmos Therapeutics INC. | $52.34 | 2023-2024 | Monoferric |
| Advanced Accelerator Applications | $50.77 | 2019-2020 | |
| Adc Therapeutics America, INC. | $46.67 | 2024-2025 | |
| Mirati Therapeutics, INC. | $46.61 | 2023 | Krazati |
| Iovance Biotherapeutics, INC. | $46.00 | 2025 | Amtagvi |
| Global Blood Therapeutics, INC. | $42.80 | 2022 | |
| Mylan Institutional INC. | $36.78 | 2019 | |
| Sirtex Medical INC | $36.43 | 2019-2023 | Sir-Spheres Microspheres |
| Morphosys, US INC. | $35.36 | 2022-2023 | Monjuvi |
| Agios Pharmaceuticals, INC. | $32.18 | 2019 | |
| Adaptive Biotechnologies Corporation | $27.59 | 2023 | Clonoseq |
| Janssen Pharmaceuticals, INC | $25.25 | 2019-2023 | Xarelto |
| Corcept Therapeutics | $24.96 | 2025 | Korlym |
| Progenics Pharmaceuticals, INC. | $24.25 | 2025 | |
| Sandoz INC. | $24.11 | 2020 | |
| Secura Bio, INC. | $23.71 | 2019-2020 | |
| Dova Pharmaceuticals | $21.86 | 2021 | |
| Galvanize Therapeutics, INC | $20.99 | 2023 | Aliya System |
| Accord Healthcare, INC. | $19.25 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $19.00 | 2019 | |
| Apellis Pharmaceuticals, INC. | $18.24 | 2023 | |
| Sanofi US Services INC. | $15.81 | 2025 | |
| Menarini Silicon Biosystems, INC. | $14.86 | 2025 | |
| Legend Biotech USA INC. | $14.37 | 2025 | Carvykti |
| Fortovia Therapeutics, INC. | $13.24 | 2020 | |
| Amneal Pharmaceuticals LLC | $12.85 | 2023 | Avastin, Neupogen, Neulasta |
| Pharmaand Gmbh | $10.18 | 2025 | Rubraca |
Drugs and devices associated with these payments
Jemperli $4,670Calquence $2,306Imfinzi $931Opdivo $739Zejula $683Padcev $659Reblozyl $647Enhertu $576Keytruda $542Xtandi $469Tukysa $404Lynparza $397Lenvima $335Ibrance $332Tagrisso $310Sarclisa $259Orserdu $259Jaypirca $239Orgovyx $228Epkinly $220Rolvedon $196Erleada $195Adcetris $189Imbruvica $184Elrexfio $171Darzalex $169Pluvicto $168Inlyta $162Venclexta $159Rybrevant $153Zepzelca $152Verzenio $152Ogsiveo $151Bosulif $149Yescarta $149Mekinist $149Talzenna $148Brukinsa $147Kisqali $136Nubeqa $136Akeega $131Cabometyx $131Balversa $128Qinlock $127Poteligeo $114Ninlaro $113Iclusig $111Braftovi $111Mektovi $111Tecvayli $106Ayvakit $105Doptelet $95.30Lorbrena $91.15Jakafi $91.00Oxbryta $89.86Keytruda Qlex $88.52Vonjo $83.34Injectafer $81.97Tibsovo $81.58Jevtana $80.62Datroway $79.68Stimufend $79.67Libtayo $79.54Xalkori $79.18Odomzo $77.59Yonsa $77.59Xofigo $73.98Romvimza $71.73Wayrilz $71.47Fotivda $69.08Trodelvy $68.81Ultomiris $67.81Promacta $66.17Zoladex $66.03Inqovi $65.63Lonsurf $65.63Monjuvi $65.42Stivarga $62.29Vitrakvi $62.29Kimmtrak $62.03Carvykti $61.45Xpovio $60.16Udenyca $59.68Idhifa $58.46Tevimbra $55.18Ojjaara $53.37Tivdak $53.07Fabhalta $52.94Monoferric $52.34Sylvant $50.30Lutathera $47.53Krazati $46.61Amtagvi $46.00Xgeva $42.34Vectibix $42.34Nplate $42.34Polivy $42.09Enjaymo $42.06Gilotrif $38.83Lynozyfic $37.86
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Superfin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.